<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">Arq. Bras. Cardiol.</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24100691</article-id><article-id pub-id-type="pmc">4081161</article-id><article-id pub-id-type="doi">10.5935/abc.20130199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Miniaturized Self-Expanding Drug-Eluting Stent in Small Coronary
Arteries: Late Effectiveness</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Flavio Roberto Azevedo</given-names></name><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Mattos</surname><given-names>Luiz Alberto Piva e</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abizaid</surname><given-names>Alexandre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abizaid</surname><given-names>Andrea S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>J. Ribamar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Ricardo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Staico</surname><given-names>Rodolfo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Botelho</surname><given-names>Roberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sousa</surname><given-names>J. Eduardo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sousa</surname><given-names>Amanda</given-names></name></contrib><aff> Instituto Dante Pazzanese de Cardiologia, S&#x000e3;o Paulo, SP - Brazil</aff></contrib-group><author-notes><corresp id="c01"><bold>Mailing Address: Flavio Roberto Azevedo de Oliveira</bold>, Marqu&#x000ea;s de
Tamandar&#x000e9;, Po&#x000e7;o da Panela. Postal Code 52061-170, Recife, PE - Brazil. E-mail:
<email>flaviora@cardiol.br</email>, <email>flaviooliveira63@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2013</year></pub-date><volume>101</volume><issue>5</issue><fpage>379</fpage><lpage>387</lpage><history><date date-type="received"><day>10</day><month>9</month><year>2012</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2013</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p></license></permissions><abstract><sec><title>Background</title><p>Small vessels represent a risk factor for restenosis in percutaneous coronary
angioplasty (PCA). The Sparrow<sup>&#x000ae;</sup> self-expanding drug-eluting stent,
which has a lower profile than the current systems, has never been tested in this
scenario. </p></sec><sec><title>Objectives</title><p>To evaluate the late effectiveness of the Sparrow<sup>&#x000ae;</sup> drug-eluting stent,
regarding in-stent late lumen loss (LLL). </p></sec><sec><title>Methods</title><p>Patients with ischemia, symptomatic or documented, were submitted to PCA in
vessels with reference diameter &#x0003c; 2.75 mm, divided into two groups regarding
Sparrow<sup>&#x000ae;</sup> stent type: group 1: Sparrow<sup>&#x000ae;</sup> drug-eluting stent
(DES), group 2: Sparrow<sup>&#x000ae;</sup> bare metal stent (BMS). Clinical follow-up
duration was 12 months. Evaluation using quantitative coronary angiography (QCA)
was performed immediately and at 8 months. A decrease of over 65% of in-stent LLL
with DES was estimated to calculate sample size. IBM<sup>&#x000ae;</sup> SPSS software,
release 19 (Chicago, Illinois, USA) was used for the statistical analysis. </p></sec><sec><title>Results</title><p>A total of 24 patients were randomized, 12 in each group. The DES and BMS groups
were similar in age (63.25 &#x000b1; 10.01 vs. 64.58 &#x000b1; 11.54, p = 0.765), male gender
(58.3% vs. 33.3%, p = 0.412), risk factors and all angiographs aspects. Immediate
results were satisfactory in both groups. At 8 months in-stent late lumen loss was
significantly lower in DES than in BMS group (DES vs. BMS 0.25 &#x000b1; 0.16 0.97 &#x000b1; 0.76,
p = 0.008). </p></sec><sec><title>Conclusion</title><p>In small-vessel PCA, the Sparrow<sup>&#x000ae;</sup> DES determined significant reduction
in in-stent LLL, when compared to Sparrow<sup>&#x000ae;</sup> BMS.</p></sec></abstract><kwd-group><kwd>Angioplasty, Balloon, Coronary</kwd><kwd>Drug Eluting Stents</kwd><kwd>Randomized Controlled Trial</kwd><kwd>Comparative Study</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>During percutaneous coronary angioplasty (PCA), small caliber vessels represent higher
complexity with increased rates of target-lesion revascularization (TLR) and more
restenosis, when compared with larger-caliber vessels<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r05" ref-type="bibr">5</xref></sup>, being related
to neointimal hyperplasia (NIH), which determines late luminal loss (LLL) after PCA. NIH
has the same intensity in vessels of different sizes, with greater impact on
small-caliber ones, which respond with greater lumen loss than larger vessels<sup><xref rid="r06" ref-type="bibr">6</xref></sup>.</p><p>With bare-metal stents (BMS), LLL ranges from 0.8 to 1.0 mm. With drug-eluting stents
(DES), LLL is always below 0.5 mm being smaller (below 0.3 mm) in those DES with
sirolimus, everolimus or biolimus. This greater inhibitory power in NIH has resulted in
a significant reduction in restenosis rates in all groups of patients (P), even in
patients with small-caliber vessels. Still, restenosis rates remain higher in
smaller-caliber vessels when compared with larger ones<sup><xref rid="r07" ref-type="bibr">7</xref>-<xref rid="r09" ref-type="bibr">9</xref></sup>.</p><p>More distal lesions, tortuosity and calcification, common in small-caliber vessels,
hinder stent navigation in conventional dilation systems with balloon-expanding stent
(BES).</p><p>Stents with thin struts induce lower NIH than the ones with thick struts, even among
DES<sup><xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref></sup>.</p><p>In this context, the Sparrow<sup>&#x000ae;</sup> self-expanding nitinol stent (Cardiomind Inc.,
Sunnyvale, California) appeared, dedicated to small-caliber vessels. The BMS version of
the Sparrow<sup>&#x000ae;</sup> self-expanding stent (SES) was evaluated by Chami&#x000e9; et
al<sup><xref rid="r12" ref-type="bibr">12</xref></sup>, who demonstrated its
efficacy and safety. It is mounted on a guide wire system that eliminates the balloon,
resulting in 70% lower profile than the conventional balloon-stent system.</p><p>This study is the pioneer to evaluate the impact of LLL when using self-expanding
Sparrow<sup>&#x000ae;</sup> DES compared to the BMS version in small-caliber vessels assessed
by QCA at eight months, which is the primary objective. Secondary objectives: (1)
comparison between the groups regarding vessel, lumen and stent volumes and the
percentage of the stent volume obstruction by means of intracoronary ultrasound (IVUS)
immediately after implantation and at eight months; (2) description of up to 12 months
in exchange major adverse cardiac events (MACE - death, myocardial infarction, target
vessel revascularization (TVR) and stent thrombosis.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>The present was a prospective randomized, non-blinded study (the surgeon was unaware
of the type of stent used), carried out at the Instituto Dante Pazzanese de
Cardiologia, S&#x000e3;o Paulo (SP), CEP and Conep protocols #3,577 and 14,582 (approved),
which evaluated the late effectiveness of the Sparrow<sup>&#x000ae;</sup> DES when compared
to the BMS version by measuring and comparing LLL at eight months through the QCA in
patients with lesions in small-caliber vessels (reference diameter &#x02264; 2.75 mm).</p><p>The clinical reassessment was scheduled for 30 days, six months and 12 months after
the procedure. QCA assessment was scheduled immediately before and immediately after
the PCA and after eight months. Intravascular ultrasound (IVUS) was also scheduled
immediately after stent implantation and after eight months.</p></sec><sec><title>Patient selection</title><p><bold>Inclusion criteria:</bold></p><list list-type="bullet"><list-item><p>Age &#x02265; 18 years.</p></list-item><list-item><p>Clinical evidence of ischemia (angina or ischemic equivalent) or evidence of
ischemia by noninvasive evaluation.</p></list-item><list-item><p>Target lesion in natural coronary artery with stenosis &#x02265; 50% and &#x0003c; 100%,
analyzed by QCA.</p></list-item><list-item><p>Target vessel with reference diameter &#x02265; 2.0 and &#x02264; 2.75 mm.</p></list-item><list-item><p>Target lesion with extension &#x02264; 20 mm.</p></list-item></list><p><bold>Exclusion criteria:</bold></p><list list-type="bullet"><list-item><p>Female gender during pregnancy.</p></list-item><list-item><p>Left ventricular ejection fraction &#x0003c; 30% during the prior six months.</p></list-item><list-item><p>Contraindication to dual antiplatelet use.</p></list-item><list-item><p>Renal dysfunction (serum creatinine &#x0003e; 2.0 mg/dL).</p></list-item><list-item><p>Stroke or transient ischemic attack in the previous six months.</p></list-item><list-item><p>Life expectancy &#x0003c; 12 months.</p></list-item><list-item><p>Target-lesion located in the left main coronary artery or ostia of the right
coronary artery, anterior descending or circumflex arteries. Bifurcation
lesion, with thrombus, or in single remaining vessel.</p></list-item><list-item><p>Target-lesion involving bifurcation.</p></list-item></list></sec><sec><title>Analyzed device and implantation technique</title><p>The analyzed device was the sirolimus-eluting Sparrow<sup>&#x000ae;</sup> DES
(Cardiomind<sup>&#x000ae;</sup> Inc., Sunnyvale, California, USA), as compared with the
BMS version of the same stent (BMS Sparrow<sup>&#x000ae;</sup>). This is a sirolimus-eluting
system (6 mg, 60% of the dose of the Cypher<sup>&#x000ae;</sup> stent) comprising a nitinol
SES with a closed-cell design and strut thickness of 67 &#x003bc;m, mounted on a platform
that runs on a guide wire (0.014"), incorporated to a matrix of medical grade
PLA/PGLA biodegradable copolymers of the SynBiosys<sup>TM</sup> biodegradable polymer
system. This copolymer matrix adds only 8 microns to strut thickness. The result is a
very low profile system, as shown in <xref ref-type="fig" rid="f01">Figure 1</xref>,
and up to 70% thinner than any balloon-stent system (<xref ref-type="table" rid="t01">Table 1</xref>).</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Evidence of low-profile of the Sparrow<sup>&#x000ae;</sup> stent deployment system
(center) compared to a balloon-expanding stent system (top) and an angioplasty
guidewire of 0.014&#x0201d; (bottom).</p></caption><graphic xlink:href="abc-101-05-0379-g01"/></fig><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Sparrow<sup>&#x000ae;</sup> stent specifications</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Stent design and material</th><th rowspan="1" colspan="1">Closed-cell design, diamond-shaped, in nickel-titanium (nitinol)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Stent shortening</td><td align="center" rowspan="1" colspan="1">9-16%</td></tr><tr><td rowspan="1" colspan="1">Radiopaque coating</td><td align="center" rowspan="1" colspan="1">Platinum coating with 3.5 &#x000b5;m</td></tr><tr><td rowspan="1" colspan="1">Extension of deployment system in the balloon working segment</td><td align="center" rowspan="1" colspan="1">170 cm</td></tr><tr><td rowspan="1" colspan="1">Total extension of the deployment system</td><td align="center" rowspan="1" colspan="1">190 cm (extensible to 300 cm)</td></tr><tr><td rowspan="1" colspan="1">Deployment system profile</td><td align="center" rowspan="1" colspan="1">0.014"</td></tr><tr><td rowspan="1" colspan="1">Guide tip extension</td><td align="center" rowspan="1" colspan="1">2-3 cm</td></tr></tbody></table></table-wrap><p>A flexible guide wire, with 2-3 cm in length, runs along the stent to allow
advancement of the system in the vessel. There are two radiopaque markers that
identify the beginning and end of the stent in the guide wire system and allow its
precise positioning in the lesion. The compound stent contains nitinol, which has a
thermoelastic expansion property (memory metal). Mechanical locks on the stent
borders keep it from expanding and attached to the guide wire. A power source
(non-sterile external device) is connected to the proximal end of a dilation system
sterile adaptable cable, which controls the stent release through an electrolysis
mechanism with a 0.5 mA current. Initially, the distal lock is released and then, the
proximal one (<xref ref-type="fig" rid="f02">Figure 2</xref>).</p><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A: Schematic representation showing all the components of the
Sparrow<sup>&#x000ae;</sup> System. B: Sparrow<sup>&#x000ae;</sup> Stent in its natural form
(expanded).</p></caption><graphic xlink:href="abc-101-05-0379-g02"/></fig><p>The stent system worked with a 0.014" guide wire and the balloon was advanced over
this system until the lesion, where predilation was performed. Then, the balloon was
retreated to a position, proximal to the proximal stent marker and the stent
deployment process was initiated through electrolysis, as previously described.
Post-procedural dilation was performed after stent release. To prevent trauma to the
stent borders, the balloon was always shorter than the stent. The same guide wire
could also be used to perform IVUS.</p><p>Study procedures comprised the following sequence: electrocardiogram (ECG) before the
procedure and at discharge; cardiac enzymes (CK-MB) and troponin I or T, before and
after the procedure, activated clotting time (ACT) after arterial access, at the end
of the procedure and before sheath withdrawal; dual antiplatelet therapy with
clopidogrel 300 mg and aspirin 100 mg at least 12 hours before the procedure,
maintained for at least eight months; use of a 0.6 F sheath and compatible
catheter-guides; intravenous heparin (100 U/kg) after sheath placement and
intracoronary nitroglycerin (100-200 mg); initial angiography of the vessel in at
least two proximal-orthogonal views to allow adequate visualization of the vessel and
lesion; evaluation by predilation QCA; ACT with stenting as previously described;
sheath withdrawal 3-4 h after the procedure with ACT &#x0003c; 200 s; discharge after 24 h
in cases without complications, follow-up visits at 30 days, eight and 12 months;
control angiography at eight months; IVUS immediately after stent implantation and
after eight months.</p><p>The analysis of the QCA and IVUS were performed offline (QCA using the
CMS-GFT<sup>&#x000ae;</sup> software, release 5.1, Medis, Leiden, the Netherlands, and
IVUS using the Echoplaque <sup>&#x000ae;</sup> software, Indec Systems, Inc, Mountain View,
California, USA).</p><p>In QCA, the following parameters were evaluated: lesion length, reference vessel
diameter (RVD), minimal lumen diameter (MLD), percentage of vessel stenosis (PS)
calculated by the formula PS = RD - MLD &#x000f7; RD) x 100, acute luminal gain (ALG)
calculated by ALG = post-MLD - pre-DML; LLL (difference between the late MLD and MLD
immediately after the procedure). These analyses were performed in-stent and in the
stent segments 0.5 mm proximal and distal to the stent (analysis of the borders).</p><p>The IVUS images corresponded to the recordings of at least 10 mm distal to the stent
up to at least 10 mm proximal to the stent, in two acquisitions, the first
immediately after the implantation and the second after 8 months. For this purpose an
automated stent traction system at a speed of 0.5 mm / sec with a 40 MHz transducer,
2.6-French sheath (Galaxy 2 ouIlab, Boston Scientific Corporation, Natick,
Massachusetts, USA) was used. Were programmed Calculations of areas and volumes of
the vessel, lumen, stent and plaque were programmed, as well as the volume of NIH and
the stent volume obstruction percentage, according to the protocol already described
in literature. Strut apposition to the vessel wall was also evaluated.</p></sec><sec><title>Study definitions</title><p><italic>Angiographic success</italic>: stent implantation in the target-lesion with
residual stenosis &#x0003c; 30% and TIMI flow 3. <italic>Procedural success</italic>:
angiographic success without major complications (death, myocardial infarction or
in-hospital emergency revascularization surgery). <italic>Stent thrombosis</italic>:
Academic Research Consortium (ARC) criteria<sup><xref rid="r13" ref-type="bibr">13</xref></sup>. Major adverse cardiac events (MACE): death (cardiac),
nonfatal myocardial infarction (elevation of cardiac enzymes CK-MB or cardiac
troponins I and T, up to three times above normal levels until discharge and twice
the normal after hospital discharge or appearance of new Q waves in at least two
contiguous ECG leads) and TVR. <italic>Binary restenosis</italic>: recurrent target
lesion &#x02265; 50% at late control.</p></sec><sec><title>Statistical Analysis</title><p>The IBM <sup>&#x000ae;</sup> SPSS Statistics software, release 19 (Chicago, Illinois, USA.)
was used for the statistical analyses. Student's <italic>t </italic>test was used to
compare means between the groups. For all compared parameters, p values &#x0003c; 0.05
were considered significant. Categorical variables were expressed as absolute value
or proportion. Continuous variables were expressed as mean and standard deviation. A
level of significance of 5% and power of 80% were considered, estimating a LLL
decrease with DES of 65% and calculating the minimum sample size of 11 patients for
each group.</p></sec></sec><sec sec-type="results"><title>Results</title><p>From January 2009 to April 2010, 24 patients were included, 12 in each group, and
prospectively randomized. The clinical characteristics of the patients are shown in
<xref ref-type="table" rid="t02">Table 2</xref> and disclosed homogeneous groups.</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Main clinical characteristics of the 24 patients treated with Sparrow &#x000ae; DES and
BMS</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">DES (n = 12)</th><th rowspan="1" colspan="1">BMS (n = 12)</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male gender, n (%)</td><td align="center" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" rowspan="1" colspan="1">0.413</td></tr><tr><td rowspan="1" colspan="1">Age in years, mean (SD)</td><td align="center" rowspan="1" colspan="1">63.25 (10.01)</td><td align="center" rowspan="1" colspan="1">64.58 (11.54)</td><td align="center" rowspan="1" colspan="1">0.765</td></tr><tr><td colspan="4" rowspan="1"><bold>Risk factors for CAD, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">12 (100.0)</td><td align="center" rowspan="1" colspan="1">10 (83.33)</td><td align="center" rowspan="1" colspan="1">0.460</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">5(41.66)</td><td align="center" rowspan="1" colspan="1">3(25.0)</td><td align="center" rowspan="1" colspan="1">0.665</td></tr><tr><td rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">10 (83.33)</td><td align="center" rowspan="1" colspan="1">9(75.0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">8(66.66)</td><td align="center" rowspan="1" colspan="1">3(25.0)</td><td align="center" rowspan="1" colspan="1">0.101</td></tr><tr><td colspan="4" rowspan="1"><bold>Coronary antecedents</bold></td></tr><tr><td rowspan="1" colspan="1">CABG surgery</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">PCI</td><td align="center" rowspan="1" colspan="1">4(33.33)</td><td align="center" rowspan="1" colspan="1">3(25.0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">4(33.33)</td><td align="center" rowspan="1" colspan="1">2 (16.66)</td><td align="center" rowspan="1" colspan="1">0.637</td></tr><tr><td colspan="4" rowspan="1"><bold>Clinical presentation</bold></td></tr><tr><td rowspan="1" colspan="1">Asymptomatic</td><td align="center" rowspan="1" colspan="1">5(41.66)</td><td align="center" rowspan="1" colspan="1">1 (8.33)</td><td align="center" rowspan="1" colspan="1">0.157</td></tr><tr><td rowspan="1" colspan="1">Stable angina</td><td align="center" rowspan="1" colspan="1">7(58.33)</td><td align="center" rowspan="1" colspan="1">11 (91.66)</td><td align="center" rowspan="1" colspan="1">0.157</td></tr><tr><td rowspan="1" colspan="1">Unstable angina</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>DES: drug-eluting stent; BMS: bare-metal stent; SD: standard deviation; CAD:
coronary artery disease; CABG: coronary artery bypass graft; PCI: percutaneous
coronary intervention.</p></fn></table-wrap-foot></table-wrap><p>The distribution per artery and per segment was similar between the groups and the
lesion was located in the middle and distal segments of the vessel in more than 70% of
cases in both groups (<xref ref-type="table" rid="t03">Table 3</xref>).</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Main qualitative angiographic characteristics of the 24 patients treated with DES
and BMS Sparrow &#x000ae; stents.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">DES (n = 12)</th><th rowspan="1" colspan="1">BMS (n = 12)</th><th rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td colspan="4" rowspan="1"><bold>Treated vessel</bold></td></tr><tr><td rowspan="1" colspan="1">ADA</td><td align="center" rowspan="1" colspan="1">3 (25.0%)</td><td align="center" rowspan="1" colspan="1">5 (41.66%)</td><td align="center" rowspan="1" colspan="1">0.665</td></tr><tr><td rowspan="1" colspan="1">Cx</td><td align="center" rowspan="1" colspan="1">2 (16.66%)</td><td align="center" rowspan="1" colspan="1">2 (16.66%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">RCA</td><td align="center" rowspan="1" colspan="1">2 (16.66%)</td><td align="center" rowspan="1" colspan="1">1 (8.33%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Diagonal branch</td><td align="center" rowspan="1" colspan="1">3 (25.0%)</td><td align="center" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Marginal branch</td><td align="center" rowspan="1" colspan="1">2 (16.66%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.460</td></tr><tr><td rowspan="1" colspan="1"><bold>Vessel segment, n (%)</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal</td><td align="center" rowspan="1" colspan="1">3 (25%)</td><td align="center" rowspan="1" colspan="1">2 (16.66%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Medial</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Distal</td><td align="center" rowspan="1" colspan="1">3 (25%)</td><td align="center" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn><p>ADA: anterior descending artery; Cx: circumflex artery; RCA: right coronary
artery; DES: drug-eluting stent; BMS: bare-metal stent.</p></fn></table-wrap-foot></table-wrap><p>There were no significant differences between the DES and BMS groups, in this sequence,
regarding the volume of contrast (133.33 &#x000b1; 23.87 mL <italic>versus</italic> 120 &#x000b1; 34.38
mL, p = 0.282), procedure time (71 &#x000b1; 9.2 min <italic>versus</italic> 62 &#x000b1; 14.82 min, p =
0.350) and maximum pressure postdilation (15.75 &#x000b1; 4.67 <italic>versus</italic> 15.42 &#x000b1;
3.12, p = 0.839).</p><p>PCI was successfully performed in all patients. There were no MACE or complications
until discharge.</p><p>QCA results of the angiographies performed immediately before and after PCA show that
randomization produced similar groups and highlights the homogeneity and immediate
outcome success between the groups. Lesion extension was slightly higher in the group
with DES, but not significantly (DES: 15.29 &#x000b1; 5.55 mm <italic>versus</italic> BMS: 12.91
&#x000b1; 3.23 mm, p = 0.233); stent length (SF 19.92 mm &#x000b1; 3.60 <italic>versus</italic> BMS:
18.00 &#x000b1; 2.34 mm, p = 0.139) and implanted stent diameter (DES 2.58 &#x000b1; 0.25 mm
<italic>versus</italic> 2.66 &#x000b1; 0.19 mm, p = 0.368) were not different between
groups.</p><p>Reference vessel diameter immediately before the procedure was similar between the
groups (DES = 2.46 + 0.24 mm <italic>versus</italic> BMS = 2.42 + 0.21 mm, p = 0.680),
demonstrating a small-caliber vessel scenario.</p><p>The severity of the lesions included in the study is well demonstrated in the
pre-procedural results of MLD (DES = 0.75 + 0.20 mm <italic>versus</italic> BMS = 0.73 +
0.17 mm, p = 0.750) and PS (SF = 69.36 + 6.37 = 69.67% <italic>versus</italic> BMS +
5.46%, p = 0.905).</p><p>The immediate results after the procedure measured by MLD (DES = 2.46 &#x000b1; 0.22 mm
<italic>versus</italic> BMS = 2.39 + 0.13 mm, p = 0.350) and PS (DES = 4.59 &#x000b1; 3.52%
<italic>versus</italic> BMS = 4.94 + 4.41%, p = 0.869) confirm successful
angiographic procedure in both groups, with similar benefits, which is reflected in
satisfactory absolute gain in both groups (DES = 1.71 + 0.28 mm <italic>versus</italic>
BMS = 1.66 + 0.12 mm, p = 0.614), a result of the difference between the pre procedural
and post-procedural MLD.</p><p>At eight months, the parameters analyzed by QCA, as demonstrated in <xref ref-type="table" rid="t04">Table 4</xref>, showed significant differences between the
groups regarding the ability to maintain the results recorded in the evaluation
immediately after the procedure, i.e., MLD and PS. These results are reflected in the
comparison of LLL between groups, the primary objective of this study, which was
significantly lower in the group with DES (DES vs BMS = 0.25 + 0.16 <italic>vs</italic>
= 0.97 + 0.76 mm, p = 0.008).</p><table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><p>In-stent quantitative coronary angiography variables at eight months</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">DES (n = 12)</th><th rowspan="1" colspan="1">BMS (n = 12)</th><th rowspan="1" colspan="1">p</th><th rowspan="1" colspan="1">CI (95%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>IRD (mm), 8 months</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">mean (SD)</td><td align="center" rowspan="1" colspan="1">2,44 (0,19)</td><td align="center" rowspan="1" colspan="1">2,24 (0,42)</td><td align="center" rowspan="1" colspan="1">0,153</td><td align="center" rowspan="1" colspan="1">(-0,08; 0,47)</td></tr><tr><td rowspan="1" colspan="1"><bold>MLD (mm), 8 months</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">mean (SD)</td><td align="center" rowspan="1" colspan="1">2,19 (0,19)</td><td align="center" rowspan="1" colspan="1">1,42(0,81)</td><td align="center" rowspan="1" colspan="1">0,008</td><td align="center" rowspan="1" colspan="1">(0,14; 0,19)</td></tr><tr><td rowspan="1" colspan="1"><bold>PS (%), 8 months</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">mean (SD)</td><td align="center" rowspan="1" colspan="1">10,70 (3,95)</td><td align="center" rowspan="1" colspan="1">39,89(30,89)</td><td align="center" rowspan="1" colspan="1">0,007</td><td align="center" rowspan="1" colspan="1">(-0,24; -1,29)</td></tr><tr><td rowspan="1" colspan="1"><bold>LLL (mm)</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">mean (SD)</td><td align="center" rowspan="1" colspan="1">0,25 (0,16)</td><td align="center" rowspan="1" colspan="1">0,97 (0,76)</td><td align="center" rowspan="1" colspan="1">0,008</td><td align="center" rowspan="1" colspan="1">(-1,19; -0,22)</td></tr></tbody></table><table-wrap-foot><fn><p>IRD: interpolated reference diameter; MLD: minimum luminal diameter; PS:
percentage of stenosis; LLL: late luminal loss; SD: standard deviation; DES:
drug-eluting stent; BMS: bare-metal stent</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="fig" rid="f03">Figure 3</xref> shows study patients' individual response
regarding PS, with the DES group showing more homogeneous and maintenance of the
response pattern.</p><fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Demonstration of individual variation in the percentage of stenosis before and
after the procedure and at eight months of evolution in the two treatment groups
(Sparrow&#x000ae; DES versus Sparrow&#x000ae; BMS), showing greater dispersion and loss of result
in the BMS group at the late follow-up.</p></caption><graphic xlink:href="abc-101-05-0379-g03"/></fig><p>The analysis of the 5 mm proximal and distal to the stent immediately after stent
implantation and at eight months, as shown in <xref ref-type="table" rid="t05">Table
5</xref>, disclosed no significant differences between the groups regarding MLD and
PS, resulting in LLL with no significant difference. Although the analysis of the
proximal and distal segments to the stent did not show significant differences between
the groups, there was a trend of higher LLL in the BMS group compared with DES group,
most markedly in the proximal segment.</p><table-wrap id="t05" orientation="portrait" position="float"><label>Table 5</label><caption><p>Quantitative coronary angiography in the 5 mm proximal and distal to the stent
immediately after implantation and at eight months</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">DES (n = 12)</th><th rowspan="1" colspan="1">BMS (n = 12)</th><th rowspan="1" colspan="1">p</th><th rowspan="1" colspan="1">CI (95%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Immediate MLD (mm)</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal, mean (SD)</td><td align="center" rowspan="1" colspan="1">2.49 (0.18)</td><td align="center" rowspan="1" colspan="1">2.43 (0.20)</td><td align="center" rowspan="1" colspan="1">0.491</td><td align="center" rowspan="1" colspan="1">(-0.11; 0.23)</td></tr><tr><td rowspan="1" colspan="1">Distal, mean (SD)</td><td align="center" rowspan="1" colspan="1">2.51 (0.18)</td><td align="center" rowspan="1" colspan="1">2.45 (0.20)</td><td align="center" rowspan="1" colspan="1">0.474</td><td align="center" rowspan="1" colspan="1">(-0.11; 0.23)</td></tr><tr><td rowspan="1" colspan="1"><bold>PS (%), immediate</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal, mean (SD)</td><td align="center" rowspan="1" colspan="1">3.62 (2.77)</td><td align="center" rowspan="1" colspan="1">3.58 (2.07)</td><td align="center" rowspan="1" colspan="1">0.971</td><td align="center" rowspan="1" colspan="1">(-2.11; 2.19)</td></tr><tr><td rowspan="1" colspan="1">Distal, mean (SD)</td><td align="center" rowspan="1" colspan="1">2.91 (2.92)</td><td align="center" rowspan="1" colspan="1">2.88 (1.99)</td><td align="center" rowspan="1" colspan="1">0.980</td><td align="center" rowspan="1" colspan="1">(-2.16; 2.21)</td></tr><tr><td rowspan="1" colspan="1"><bold>MLD (mm), 8 months</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal, mean (SD)</td><td align="center" rowspan="1" colspan="1">2.21 (0.26)</td><td align="center" rowspan="1" colspan="1">1.74 (0.79)</td><td align="center" rowspan="1" colspan="1">0.075</td><td align="center" rowspan="1" colspan="1">(-0.05; 0.98)</td></tr><tr><td rowspan="1" colspan="1">Distal, mean (SD)</td><td align="center" rowspan="1" colspan="1">2.31 (0.28)</td><td align="center" rowspan="1" colspan="1">1.90 (0.74)</td><td align="center" rowspan="1" colspan="1">0.104</td><td align="center" rowspan="1" colspan="1">(-0.094; 0.89)</td></tr><tr><td rowspan="1" colspan="1"><bold>PS (%), 8 months</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal, mean (SD)</td><td align="center" rowspan="1" colspan="1">9.41 (7.40)</td><td align="center" rowspan="1" colspan="1">23.28 (30.72)</td><td align="center" rowspan="1" colspan="1">0.144</td><td align="center" rowspan="1" colspan="1">(-33.19; 5.46)</td></tr><tr><td rowspan="1" colspan="1">Distal, mean (SD)</td><td align="center" rowspan="1" colspan="1">4.19 (1.50)</td><td align="center" rowspan="1" colspan="1">16.32 (27.12)</td><td align="center" rowspan="1" colspan="1">0.154</td><td align="center" rowspan="1" colspan="1">(-29.37; 5.12)</td></tr><tr><td rowspan="1" colspan="1"><bold>LLL (mm)</bold></td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Proximal, mean (SD)</td><td align="center" rowspan="1" colspan="1">0.28 (0.19)</td><td align="center" rowspan="1" colspan="1">0.69 (0.67)</td><td align="center" rowspan="1" colspan="1">0.064</td><td align="center" rowspan="1" colspan="1">(-0.84; 0.028)</td></tr><tr><td rowspan="1" colspan="1">Distal, mean (SD)</td><td align="center" rowspan="1" colspan="1">0.17 (0.17)</td><td align="center" rowspan="1" colspan="1">0.54 (0.65)</td><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">(-0.80; 052)</td></tr></tbody></table><table-wrap-foot><fn><p>MLD: minimum luminal diameter; PS: percentage of stenosis; LLL: late luminal
loss; SD: standard deviation; DES: drug-eluting stent; BMS: bare-metal
stent.</p></fn></table-wrap-foot></table-wrap><p>Technical difficulties in the progression of IVUS catheter to an adequate point beyond
the stent (including 5 mm distal to it, to include the entire segment of interest)
restricted data collection provided by this type of evaluation predicted in the study,
precluding the provision of full information, differently from what occurred with the
QCA.</p><p>Nevertheless, it was observed that the self-expanding stent showed an increase in volume
over time from 14.8% in the DES group and 2.5% in the BMS group. There was no strut
malapposition in this group of patients.</p><p>Up to 12 months of evolution, there was no patient loss to follow-up. All patients used
dual antiplatelet therapy throughout the study, as required by the protocol. There were
no reports of death, nonfatal myocardial infarction or need for myocardial
revascularization.</p><p>Although four patients had binary restenosis in the BMS group, the clinical translation
of this finding resulted in new PTCA in three patients, only. Specifically, the patient
that had occlusive restenosis, was maintained in clinical treatment due to the good
evolution.</p><p>Clinical event compatible with in-stent thrombosis was not observed in either group
during follow-up.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>New research in this area is of relevance because the small-caliber vessels represent
40-50% of cases of PCA, and this subgroup, although it has been strongly benefited from
the advent of DES, still carries a higher risk of restenosis and TVR, when compared with
larger-caliber vessel results<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup>. This study represents the first clinical experience with drug
eluting SES in small-caliber vessels.</p><p>The primary objective of reducing in-stent LLL in this study was achieved with
Sparrow<sup>&#x000ae;</sup> DES and the absolute value found of 0.25 &#x000b1; 0.16 mm shows that the
performance of this platform was equivalent to the best results with drug-eluting
stents.</p><p>The patients in our study are also part of a larger cohort, the multicenter CARE II
study<sup><xref rid="r16" ref-type="bibr">16</xref></sup>, which included a larger
number of patients and of which initial results, presented at the 2010 Transcatheter
Cardiovascular Therapeutics Congress showed data similar to those found here.</p><p>The CARE II study<sup><xref rid="r16" ref-type="bibr">16</xref></sup>, with inclusion
criteria similar to those in our study, including the patients in this cohort, involved
137 patients in three groups, comparing Sparrow <sup>&#x000ae;</sup> DES (group 1) with
Sparrow<sup>&#x000ae;</sup> BMS (group 2) and the Driver<sup>&#x000ae;</sup>/Microdriver<sup>&#x000ae;</sup>
bare-metal balloon expandable stent (group 3). The primary objective was the assessment
of LLL at eight months by IVUS. At eight months a significantly lower LLL was observed
in the DES group, similar to what was found by QCA in our study (0.29 + 0.45 mm). In the
group with Sparrow<sup>&#x000ae;</sup> DES, the binary restenosis was 6.7% and the incidence of
MACE at eight months was 6.25%, confirming the results of our study in a larger
population.</p><p>There was no binary restenosis at the borders in the group of patients with DES,
differently from the previously described Sirius study report. This may be related to
Sparrow<sup>&#x000ae;</sup> stent system implantation technique, which minimizes the chances
of barotrauma to the stent borders. In the group with DES, two cases (16%) of binary
restenosis were recorded, both involving the proximal border, but they were not isolated
cases, reflecting a proliferative restenosis process and, therefore, associated with
undesired proliferation of in-stent NIH.</p><p>Safety problems with DES, shown by late and very late in-stent thrombosis (low, but
greater than that observed with the BMS), were probably related to chronic inflammatory
stimulation determined by the durable polymers, which hinder the re-endothelialization
process<sup><xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r20" ref-type="bibr">20</xref></sup>. In the present study, in-stent thrombosis did not occur
during a 12-month follow-up. The use of bioabsorbable polymers in the
Sparrow<sup>&#x000ae;</sup> stent may have contributed to this fact.</p><p>Even in the age of DES, there have been studies showing that the smaller the strut
thickness, the lower the LLL<sup><xref rid="r11" ref-type="bibr">11</xref></sup>. In
this context, the Sparrow<sup>&#x000ae;</sup> stent has an additional advantage, as it has
thinner struts than all other available stent models.</p><p>These favorable characteristics of the deployment system of the self-expanding
Sparrow<sup>&#x000ae;</sup> stent - thin struts, bioabsorbable polymer, antiproliferative
drug from the <italic>limo</italic> family, additional expansion property over time and
deployment technique that minimizes trauma to the borders - may be at the root of its
good performance as demonstrated in our study and ratified by the results of the CARE II
study<sup><xref rid="r16" ref-type="bibr">16</xref></sup>.</p><p>The evaluation by IVUS in this study, as in the CARE II<sup><xref rid="r16" ref-type="bibr">16</xref></sup> showed a trend to stent expansion over time, more
markedly in the group with drug-eluting stents, a finding that motivates further
research.</p><p>The limitations of this study included the small numbers of patients, which was related
to logistical issues regarding the endoprosthesis availability, the randomization, which
was not blinded, and the impossibility of IVUS evaluation, an important tool for the
assessment of the mechanistic performance of stents.</p><p>The subsequent analysis by QCA and IVUS were performed without knowledge of the type of
stent used, which lessens the non-blinded randomization problem.</p><p>Broad inclusion criteria, without restrictions regarding tortuosity and calcification,
in addition to vessel diameter, may be related to the low rate of IVUS performance in
this study.</p><p>The present study paves the way for further research with larger sample sizes and even
comparison with other DES systems, so that the clinical impact of this new device can be
assessed by demonstrating, in a pioneering way, the performance of the self-expanding
Sparrow<sup>&#x000ae;</sup> stent in small caliber vessels, validating its efficacy through
the objective parameter of LLL outcome and its safety by the absence of stent thrombosis
at 12 months.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The results of this study allow us to conclude:</p><p>1. In patients submitted to percutaneous transluminal coronary angioplasty in natural
coronary arteries with reference diameter &#x02264; 2.75 mm, the use of self-expanding DES
Sparrow <sup>&#x000ae;</sup> compared with the bare metal version of the same stent, resulted in
significant reduction of late lumen loss (within eight months after the index
procedure).</p><p>2. Angiographic measurements regarding the immediate outcome after the procedure
(percentage of stenosis, minimal lumen diameter and acute luminal gain) were
satisfactory in both groups with no significant differences between them.</p><p>3. Angiographic measurements regarding the impact of treatment with Sparrow<sup>&#x000ae;</sup>
DES in segments that are 5 mm proximal and distal to the stent showed outcome
maintenance at eight months when compared to immediate outcomes (minimal luminal
diameter and percent stenosis), thus demonstrating the absence of angiographic adverse
effects at the stent borders in this group of patients.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research: de Oliveira FRA, Mattos LAP, Abizaid A, Staico
R, Botelho R, Sousa JE, Sousa A; Acquisition of data: de Oliveira FRA, Abizaid A,
Abizaid AS, Costa JR, Costa R, Staico R, Botelho R, Sousa JE, Sousa A; Analysis and
interpretation of the data: de Oliveira FRA, Mattos LAP, Sousa JE, Sousa A;
Statistical analysis: de Oliveira FRA, Sousa JE; Obtaining funding: de Oliveira FRA;
Writing of the manuscript: de Oliveira FRA, Mattos LAP, Costa JR; Critical revision
of the manuscript for intellectual content: Mattos LAP, Abizaid A, Sousa JE, Sousa A;
Clinical monitoring of patients: Abizaid AS.</p></fn><fn fn-type="conflict"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of Funding</bold></p><p>There were no external funding sources for this study.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This article is part of the thesis of doctoral submitted by Flavio Roberto Azevedo de
Oliveira, from Instituto Dante Pazzanese de Cardiologia.</p></fn></fn-group><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>JE</given-names></name><name><surname>Sousa</surname><given-names>AG</given-names></name><name><surname>Feres</surname><given-names>F</given-names></name></person-group><article-title xml:lang="pt">Angioplastia transluminal coron&#x000e1;ria: indica&#x000e7;&#x000f5;es e
resultados atuais</article-title><source>Arq Bras Cardiol</source><year>1988</year><volume>51</volume><issue>1</issue><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">2977723</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feres</surname><given-names>F</given-names></name><name><surname>Tanajura</surname><given-names>LF</given-names></name><name><surname>Pinto</surname><given-names>IM</given-names></name><name><surname>Cano</surname><given-names>MN</given-names></name><name><surname>Maldonado</surname><given-names>G</given-names></name><name><surname>Mattos</surname><given-names>LA</given-names></name><etal>et al</etal></person-group><article-title xml:lang="pt">Angioplastia coron&#x000e1;ria: efic&#x000e1;cia dos novos
cateteres-bal&#x000e3;o de baixo perfil</article-title><source>Arq Bras Cardiol</source><year>1989</year><volume>53</volume><issue>6</issue><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">2637006</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>GG</given-names></name><name><surname>Gasparini</surname><given-names>GL</given-names></name><name><surname>Anselmi</surname><given-names>M</given-names></name><name><surname>Morando</surname><given-names>G</given-names></name><name><surname>Turri</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Is bare-metal stenting superior to balloon angioplasty for small
vessel coronary artery disease? Evidence from a meta-analysis of randomised
trials</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>9</issue><fpage>881</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">15681573</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirtane</surname><given-names>AJ</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Applegate</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Safety and efficacy of drug-eluting and bare metal stents:
comprehensive meta-analysis of randomized trials and observational
studies</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>25</issue><fpage>3198</fpage><lpage>3206</lpage><pub-id pub-id-type="pmid">19528338</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schampaert</surname><given-names>E</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name><name><surname>Schluter</surname><given-names>M</given-names></name><name><surname>Reeves</surname><given-names>F</given-names></name><name><surname>Traboulsi</surname><given-names>M</given-names></name><name><surname>Title</surname><given-names>LM</given-names></name><etal>et al</etal><collab>C-SIRIUS Investigators</collab></person-group><article-title>The Canadian study of the sirolimus-eluting stent in the treatment of
patients with long de novo lesions in small native coronary arteries
(C-SIRIUS)</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><issue>6</issue><fpage>1110</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">15028375</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>R</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Pichard</surname><given-names>AD</given-names></name><name><surname>Kent</surname><given-names>KM</given-names></name><name><surname>Satler</surname><given-names>LF</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name></person-group><article-title>Intimal hyperplasia thickness at follow-up is independent of stent
size: a serial intravascular ultrasound study</article-title><source>Am J Cardiol</source><year>1998</year><volume>82</volume><issue>10</issue><fpage>1168</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">9832088</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauri</surname><given-names>L</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Candia</surname><given-names>SC</given-names></name><name><surname>Cutlip</surname><given-names>DE</given-names></name><name><surname>Kuntz</surname><given-names>RE</given-names></name></person-group><article-title>Robustness of late lumen loss in discriminating drug-eluting stents
across variable observational and randomized trials</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>18</issue><fpage>2833</fpage><lpage>2839</lpage><pub-id pub-id-type="pmid">16267256</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Rizvi</surname><given-names>A</given-names></name><name><surname>Newman</surname><given-names>W</given-names></name><name><surname>Mastali</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>Caputo</surname><given-names>R</given-names></name><etal>et al</etal><collab>SPIRIT IV Investigators</collab></person-group><article-title>Everolimus-eluting versus paclitaxel-eluting stents in coronary artery
disease</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>18</issue><fpage>1663</fpage><lpage>1674</lpage><pub-id pub-id-type="pmid">20445180</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Mauri</surname><given-names>L</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name><name><surname>Cutlip</surname><given-names>DE</given-names></name><name><surname>Nikolsky</surname><given-names>E</given-names></name><name><surname>O'Shaughnessy</surname><given-names>C</given-names></name><etal>et al</etal><collab>ENDEAVOR IV Investigators</collab></person-group><article-title>A randomized comparison of the ENDEAVOR zotarolimus-eluting stent
versus the TAXUS paclitaxel-eluting stent in de novo native coronary
lesions12-month outcomes from the ENDEAVOR IV trial</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>6</issue><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">20152559</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Sarais</surname><given-names>C</given-names></name><name><surname>Pagnotta</surname><given-names>P</given-names></name><name><surname>Liistro</surname><given-names>F</given-names></name><name><surname>Montorfano</surname><given-names>M</given-names></name><name><surname>Chieffo</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>In-stent restenosis in small coronary: impact of strut
thickness</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><issue>3</issue><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">12142103</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Drzewiecki</surname><given-names>J</given-names></name><name><surname>Banning</surname><given-names>A</given-names></name><name><surname>Grube</surname><given-names>E</given-names></name><name><surname>Hauptmann</surname><given-names>K</given-names></name><name><surname>Silber</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Randomized study to assess the effectiveness of slow- and
moderate-release polymer-based paclitaxel-eluting stents for coronary artery
lesions. TAXUS II Study Group</article-title><source>Circulation</source><year>2003</year><volume>108</volume><issue>7</issue><fpage>788</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">12900339</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chami&#x000e9;</surname><given-names>D</given-names></name><name><surname>Costa</surname><given-names>JR</given-names></name><name><surname>Abizaid</surname><given-names>A</given-names></name><name><surname>Gottschald</surname><given-names>M</given-names></name><name><surname>Feres</surname><given-names>F</given-names></name><name><surname>Mattos</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title xml:lang="pt">Exequibilidade, efic&#x000e1;cia e seguran&#x000e7;a do sistema de
stentcardiomin DTM no tratamento de les&#x000f5;es em vasos defino calibre. Um estudo
seriado com angiografia e ultrassom intracoron&#x000e1;rio</article-title><source>Rev Bras Cardiol Invas</source><year>2008</year><volume>16</volume><issue>2</issue><fpage>193</fpage><lpage>199</lpage></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutlip</surname><given-names>DE</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Boam</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>DJ</given-names></name><name><surname>van Es</surname><given-names>GA</given-names></name><etal>et al</etal><collab>Academic Research Consortium</collab></person-group><article-title>Clinical end points in coronary stent trials: a case for standardized
definitions</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>17</issue><fpage>2344</fpage><lpage>2351</lpage><pub-id pub-id-type="pmid">17470709</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization (WHO)</collab><name><surname>Mackay</surname><given-names>J</given-names></name><name><surname>Menash</surname><given-names>G</given-names></name></person-group><source>The atlas of heart disease and stroke</source><publisher-loc>Geneva</publisher-loc><publisher-name>Centers for Disease Control and Prevention</publisher-name><year>2004</year></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Lim</surname><given-names>YL</given-names></name><name><surname>Oesterle</surname><given-names>SN</given-names></name></person-group><article-title>Stent placement for non-STRESS/BENESTENT lesions: a critical
review</article-title><source>Catheter Cardiovasc Interv</source><year>2000</year><volume>51</volume><issue>2</issue><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">11025583</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abizaid</surname><given-names>A</given-names></name><name><surname>Botelho</surname><given-names>R</given-names></name><name><surname>Verheye</surname><given-names>S</given-names></name><name><surname>Meredith</surname><given-names>I</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><name><surname>Staico</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>[Poster]. CARE II 8 month follow-up results with the CardioMind&#x000ae;
0.014" Sparrow&#x000ae; Sirolimus-eluting Nitinol Stent System </article-title><source>Cardiol</source><year>2010</year><volume>56</volume><issue>13</issue><fpage>B53</fpage><lpage>B53</lpage></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camenzind</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name></person-group><article-title>Stent thrombosis late after implantation of first-generation
drug-eluting stents: a cause for concern</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>11</issue><fpage>1440</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">17344324</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AJ</given-names></name><name><surname>Gorman</surname><given-names>PD</given-names></name><name><surname>Kenwood</surname><given-names>B</given-names></name><name><surname>Hudak</surname><given-names>C</given-names></name><name><surname>Tashko</surname><given-names>G</given-names></name><name><surname>Virmani</surname><given-names>R</given-names></name></person-group><article-title>A comparison of four stent designs on arterial injury, cellular
proliferation, neointima formation, and arterial dimensions in an experimental
porcine model</article-title><source>Catheter Cardiovasc Interv</source><year>2001</year><volume>53</volume><issue>3</issue><fpage>420</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">11458427</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>R</given-names></name><name><surname>Guagliumi</surname><given-names>G</given-names></name><name><surname>Farb</surname><given-names>A</given-names></name><name><surname>Musumeci</surname><given-names>G</given-names></name><name><surname>Grieco</surname><given-names>N</given-names></name><name><surname>Motta</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Localized hypersensitivity and late coronary thrombosis secondary to a
sirolimus-eluting stent: should we be cautious?</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>6</issue><fpage>701</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">14744976</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockwood</surname><given-names>NA</given-names></name><name><surname>Hergenrother</surname><given-names>RW</given-names></name><name><surname>Patrick</surname><given-names>LM</given-names></name><name><surname>Stucke</surname><given-names>SM</given-names></name><name><surname>Steendam</surname><given-names>R</given-names></name><name><surname>Pacheco</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>In vitro and in vivo characterization of novel biodegradable polymers
for application as drug-eluting stent coatings</article-title><source>J Biomater Sci Polym Ed</source><year>2010</year><volume>21</volume><issue>4</issue><fpage>529</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">20233507</pub-id></element-citation></ref></ref-list></back></article>